Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Future Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon.12.162PMID 23252570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013influential reference
• Cancer drugs and the heart: importance and management.

  2013cited by this paper
• Pre-eclampsia

  2012cited by this paper
• Antiangiogenic-Induced Hypertension: The Molecular Basis of Signaling Network

  2012cited by this paper
• Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.

  2011cited by this paper
• Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

  2011cited by this paper
• Reversible cardiomyopathy associated with sunitinib and sorafenib.

  2011cited by this paper
• The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System

  2011cited by this paper
• Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models

  2011cited by this paper
• Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

  2011cited by this paper
• Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

  2010cited by this paper
• Tumor Angiogenesis: Insights and Innovations

  2010cited by this paper
• Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

  2010cited by this paper
• Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

  2010cited by this paper
• Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib

  2009cited by this paper
• Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

  2009cited by this paper
• Heart failure associated with sunitinib malate

  2008cited by this paper
• A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

  2008cited by this paper
• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.

  2008cited by this paper
• Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

  2008cited by this paper
• Focus on hypertension.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007influential reference
• PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart.

  2007cited by this paper
• PI3K(p110α) Inhibitors as Anti-Cancer Agents: Minding the Heart

  2007cited by this paper
• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

  2007cited by this paper
• Cardiac dysfunction in heart failure: the cardiologist's love affair with time.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

  2006cited by this paper
• Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

  2005cited by this paper
• Pre-eclampsia

  2005cited by this paper
• Circulating angiogenic factors and the risk of preeclampsia.

  2004cited by this paper
• Antibiotic use in relation to the risk of breast cancer

  2004cited by this paper
• Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

  2003cited by this paper
• Immunochemical Localization of Platelet-Derived Growth Factor in Placenta and Its Possible Role in Pre-eclampsia

  1999cited by this paper
• Insights and innovations.

  1991cited by this paper

• Letter by Gallucci and Storto Regarding Article, "Vascular Toxicities of Cancer Therapies: The Old and the New-An Evolving Avenue".

  2016cites this paper